Edition:
United States

Basilea Pharmaceutica AG (BSLN.S)

BSLN.S on Swiss Exchange

83.45CHF
22 Jun 2017
Change (% chg)

CHF-0.85 (-1.01%)
Prev Close
CHF84.30
Open
CHF84.50
Day's High
CHF84.80
Day's Low
CHF82.80
Volume
53,149
Avg. Vol
86,380
52-wk High
CHF95.35
52-wk Low
CHF61.20

BSLN.S

Chart for BSLN.S

About

Basilea Pharmaceutica AG is a Switzerland-based company engaged in the research, development and commercialization of pharmaceutical products. The Company focuses on pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology. The Company has a range of drugs to treat drug-resistant... (more)

Overall

Beta: 1.33
Market Cap(Mil.): CHF988.02
Shares Outstanding(Mil.): 11.84
Dividend: --
Yield (%): --

Financials

  BSLN.S Industry Sector
P/E (TTM): -- 239.63 19.01
EPS (TTM): -5.07 -- --
ROI: -17.54 -8.17 -5.03
ROE: -- -11.48 -4.28

BRIEF-Basilea announces license agreement with Pfizer for antifungal Cresemba

* Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey And Israel

Jun 14 2017

BRIEF-Basilea announces distribution agreement with Avir Pharma for Cresemba And Zevtera in Canada

* BASILEA ANNOUNCES DISTRIBUTION AGREEMENT WITH AVIR PHARMA INC. FOR CRESEMBA (ISAVUCONAZOLE) AND ZEVTERA (CEFTOBIPROLE) IN CANADA

Jun 14 2017

BRIEF-Basilea Pharmaceutica awarded $54.8 mln of additional funding by BARDA

* BASILEA AWARDED USD 54.8 MILLION OF ADDITIONAL FUNDING BY BARDA TO SUPPORT PHASE 3 DEVELOPMENT OF CEFTOBIPROLE

Jun 13 2017

BRIEF-Basilea Pharmaceutica announces clinical study agreement with Adult Brain Tumor Consortium

* BASILEA ANNOUNCES CLINICAL STUDY AGREEMENT WITH ADULT BRAIN TUMOR CONSORTIUM TO EXPLORE BAL101553 IN NEWLY DIAGNOSED GLIOBLASTOMA Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 12 2017

BRIEF-Basilea Pharmaceutica ‍announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553

* ‍ANNOUNCES PRESENTATION OF INTERIM PHASE 1/2A CLINICAL DATA WITH ANTICANCER DRUG CANDIDATE BAL101553 AT ASCO MEETING​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jun 06 2017

BRIEF-Basilea shareholders approve resolutions proposed by the board at the general meeting of shareholders

* Basilea shareholders approve all resolutions proposed by the board of directors at the ordinary general meeting of shareholders

Apr 27 2017

BRIEF-Basilea Pharmaceutica: agreement with FDA regarding ceftobiprole

* Basilea announces agreement with FDA on special protocol assessments for antibiotic ceftobiprole phase 3 clinical studies in bloodstream and skin infections

Apr 21 2017

BRIEF-Basilea Pharmaceutica FY 2016 net loss narrows to CHF 51.3 million

* In 2017, Basilea will further advance clinical development of its oncology drug candidates and expects to complete dose-escalation in bal101553's phase 1/2a studies and bal 3833's phase 1 study

Feb 20 2017

More From Around the Web

Earnings vs. Estimates